Medical Oncology

, Volume 28, Supplement 1, pp 286–290

Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients

Original Paper

Abstract

Neuroendocrine tumors (NETs) of the gastrointestinal tract have a propensity for hepatic metastases. Surgical resection for hepatic metastases remains the gold standard for long-term survival, but many patients present with multifocal tumors, precluding surgery with increasing use of chemoembolization. However, there are few studies examining long-term survival factors. We reviewed our 15-year experience with chemoembolization in 123 patients with unresectable NET liver metastases, whose prognosis was evaluated upon baseline clinical factors. There were 64 males (53%) and 59 females (47%). Average age at presentation was 56 years (range: 14.3–85.5 years). Abdominal pain (44%) was the most common presenting symptom, followed by diarrhea (30%) and weight lost (22%). Patients underwent an average 7.3 cycles of chemoembolization (range 1–32 cycles). Responses: 62% of patients had PR; 24% had stable disease and 14% had tumor progression. Overall 3-, 5- and 10-year survivals were 59, 36 and 20% of patients with a mean follow-up of 3.2 years (range 2 weeks–18.3 years) and mean survival of 3.3 years. Univariate analysis showed that age greater than 60 years had worse outcome (P < 0.01), as did baseline serum albumin of ≤3.5 g/dL and prothrombin time >13 s. Location of the primary tumor (P = 0.68), gender (P = 0.4) and serum NET peptide levels did not influence survival. However, multivariate analysis showed that a low baseline serum albumin level was an independent factor for prognosis (P = 0.003). Chemoembolization for unresectable NETs metastatic to liver is useful for tumor size reduction, symptom palliation and can be associated with prolonged survival.

Keywords

Neuroendocrine Cancer Chemoembolization Liver Metastasis Carcinoid 

Abbreviations

NET

Neuroendocrine tumor

CT

Computerized tomography

PR

Partial response

References

  1. 1.
    O’Toole D, Maire F, Ruszniewski P. Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer. 2003;10:463–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg. 1996;20:126–31.PubMedCrossRefGoogle Scholar
  3. 3.
    Lips CJ, Lentjes EGWM, Hoppener JWM. The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem. 2003;40:612–27.PubMedCrossRefGoogle Scholar
  4. 4.
    Moertel CG. Karnofsky memorial lecture: an odyssey in the land of small tumors. J Clin Oncol. 1987;5(10):1503–22.Google Scholar
  5. 5.
    Berge T, Linell F. Carcinoid tumors, frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand A. 1976;84:322–30.PubMedGoogle Scholar
  6. 6.
    Bax N, Woods H, Batchelor A, Jennings M. Clinical manifestations of carcinoid disease. World J Surg. 1996;20:142–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Proye C. Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization. World J Surg. 2001;25:685–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg. 1999;229(6):815–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Pape U-F, Bohmig M, Berndt U, Tiling N, Wiedenmann B, Plockinger U. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. Ann N Y Acad Sci. 2004;1014:222–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Woodside KJ, Townsend CM, Evers BM. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg. 2004;8(6):742–56.PubMedCrossRefGoogle Scholar
  11. 11.
    Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130(4):677–85.PubMedCrossRefGoogle Scholar
  12. 12.
    Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg. 2001;25(6):693–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg. 2004;8(2):208–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Azimuddin K, Chamberlain RS. The surgical management of pancreatic neuroendocrine tumors. Surg Clin North Am. 2001;81(3):511–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Sutcliffe R, Maguire D, Ramage J, Rela M, Heaton N. Management of neuroendocrine liver metastases. Am J Surg. 2004;187:39–46.PubMedCrossRefGoogle Scholar
  16. 16.
    Chamberlain R, Canes D, Brown K, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190(4):432–45.PubMedCrossRefGoogle Scholar
  17. 17.
    Nave H, Mossinger E, Feist H, Lang H, Raab H-R. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery. 2001;129:170–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol. 2003;13:136–40.PubMedGoogle Scholar
  19. 19.
    Allison D, Modlin I, Jenkins W. Treatment of carcinoid liver metastases by hepatic-artery embolisation. Lancet. 1977;2(8052–8053):1323–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Drougas JG, Anthony LB, Blair TK, Lopez RR, Wright JK, Chapman WC, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg. 1998;175:408–12.PubMedCrossRefGoogle Scholar
  21. 21.
    Carr BI, Kondragunta V, Buch S, Branch R. Therapeutic equivalence in survival for hepatic arterial chemoembolization and 90Yttrium microspheres (Y90) treatments in unresectable HCC. Cancer. 2010;116:1305–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003;9(4):261–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Vogl TJ, Gruber T, Naguib NNN, Hammersting R, Nour-Eldin NA. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. Am J Roentgen. 2009;193:941–7.CrossRefGoogle Scholar
  24. 24.
    Carr BI, Buch SC, Kondragunta V, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable HCC: a case cohort study. J Gastroenterol Hepatol. 2008;23:1259–66.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.UPMC Liver Cancer CenterUniversity of Pittsburgh, Starzl Transplant InstitutePittsburghUSA
  2. 2.Department of Medical OncologyThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations